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In Brief Lananna et al. show that the circadian clock protein BMAL1 regulates astrocyte activation via a cell-autonomous mechanism involving diminished glutathione-S-transferase signaling. This finding elucidates a function of the core circadian clock in astrocytes and reveals BMAL1 as a modulator of astrogliosis.
INTRODUCTION
Changes in behavioral circadian rhythms are common in many neurodegenerative diseases (Breen et al., 2014; Hatfield et al., 2004; Musiek and Holtzman, 2016) and can occur early in disease progression (Musiek et al., 2018) . Circadian rhythms are generated by the suprachiasmatic nucleus of the hypothalamus (SCN) (Mohawk et al., 2012) , which synchronizes cellular clocks throughout the body to the light-dark (L:D) cycle. The core molecular clock consists of a transcriptional-translational feedback loop with a positive transcriptional limb, consisting of heterodimers of the basic-helix-loop-helix (bHLH) transcription factor BMAL1 (also known as ARNTL [aryl hydrocarbon receptor nuclear translocator-like protein 1]) with either CLOCK (circadian locomotor output cycles kaput) or NPAS2 (neuronal PAS domain protein 2). The negative limb includes Period (PER), cryptochrome (CRY), and REV-ERB genes, which are transcriptional targets of BMAL1 and provide negative feedback inhibition of BMAL1 function (Mohawk et al., 2012) . The core clock regulates transcription of thousands of genes in a highly tissue-specific manner, regulating cellular functions including metabolism, inflammation, and redox homeostasis (Bass and Takahashi, 2010) . In addition to disrupted activity and sleep rhythms, dysregulated circadian gene expression patterns are also observed in neurodegenerative disease models and patients (Song et al., 2015; Breen et al., 2014; Cronin et al., 2017) . However, the impact of clock dysfunction on neurological diseases of the brain remains poorly understood.
Astrocytes play a critical role in brain health and neurodegenerative disease, as dysfunctional astrocytes can drive neurodegeneration (Lian et al., 2015; Macauley et al., 2011; Yamanaka et al., 2008) . Astrocyte activation is a ubiquitous response to brain injury, from neurodegeneration to trauma, which has historically been characterized by increased expression of the cytoskeletal protein glial fibrillary acidic protein (GFAP) (Sofroniew, 2014) . Recent work has begun to elucidate the diversity of astrocyte activation phenotypes beyond GFAP, as astrocytes activated by different stimuli express unique transcriptional profiles that can be associated with divergent phenotypes, ranging from neurotoxic to neurotrophic (Liddelow et al., 2017; Zamanian et al., 2012) . However, a further understanding of astrocyte activation mechanisms is needed in order to effectively target astrocyte function therapeutically.
Astrocyte activation and circadian clock dysfunction are two pervasive, often coexistent features of neurological diseases, though their interaction is unknown. We previously observed that deletion of the core clock gene Bmal1, which abrogates all circadian clock function, caused severe, spontaneous astrogliosis throughout the mouse brain, which was accompanied by increased oxidative stress, synaptic damage, and inflammation (Musiek et al., 2013) . However, the cellular and molecular mechanisms linking BMAL1 to astrocyte activation and function remain uncertain. Thus, we sought to characterize the astrocyte activation induced by circadian clock disruption and evaluate whether the clock protein BMAL1 might regulate astrogliosis in a cell-autonomous manner.
RESULTS
We first asked if nongenetic disruption of circadian rhythms could influence Gfap levels in the brain. Exposure of wild-type (WT) C57BL/6 mice to a 10 hr:10 hr L:D cycle induces circadian desynchrony and eventually arrhythmicity, as well as loss of detectable circadian transcript oscillations in the cerebral cortex ( Figures 1A and S1A ). After 6 weeks of circadian disruption, Gfap transcript levels were increased throughout the circadian cycle ( Figure S1B ), with an average increase of 19.7% ( Figure 1B) . Thus, light-induced behavioral circadian rhythm disruption promotes astrocyte Gfap expression.
We previously observed that abrogation of circadian function by deletion of Bmal1 in mice induced striking increases in GFAP+ astrocytes throughout the brain (Musiek et al., 2013; Yang et al., 2016) . We asked if the astrocyte activation observed following Bmal1 deletion was simply a response to neuronal injury or a cell-autonomous process regulated by the core clock in astrocytes. To address this, we examined the brains of neuron-specific Bmal1 knockout (KO) mice (Camk2a-iCre;Bmal1 f/f ). These mice express Cre recombinase in a pan-neuronal manner under the control of a BAC-CaMKIIa promoter, yielding widespread neuronal deletion of Bmal1 ( Figure S1C ) and loss of behavioral circadian rhythms (Izumo et al., 2014) . At 4 months, Camk2a-iCre+;Bmal1 f/f mice exhibited a modest increase in astrocyte activation, as assessed by GFAP immunostaining (Figures 1C and  1D ) and qPCR ( Figure 1E ), in the cortex and hippocampus. However, similarly aged Nestin-Cre+;Bmal1 f/f (referred to as NBmal1 KO) mice, in which Bmal1 is deleted in neurons and astrocytes, have much more prominent astrogliosis throughout the brain and higher expression of the activation-related transcripts Aqp4 and Serpina3n ( Figures 1C-1E ). While NBmal1 KO mice exhibit large increases in GFAP+ astrocytes in the cortex, this did not appear to be due to increased astrocyte division, as NBmal1 KO mice had no significant increase in dividing Ki67+, GFAP+ double-positive cells ( Figure S1D ) or immunoreactivity for the pan-astrocyte marker S100B ( Figure S1E ). This finding suggests that while a small component of astrogliosis observed following Bmal1 deletion may be a response to neuronal injury, BMAL1 within astrocytes appears to play a critical cell-autonomous role in astrocyte activation.
To assess the potential cell-autonomous effects of Bmal1 on astrocyte activation, we generated primary astrocyte-enriched cultures from Bmal1 KO mice and WT littermates and examined activation markers in vitro. Bmal1 KO astrocytes were viable and appeared to have normal morphology but had significantly elevated expression of Gfap and Aqp4 mRNA and GFAP protein (Figures 2A and 2B ), suggesting spontaneous activation in the absence of neuronal influence. In order to exclude a developmental influence of BMAL1, we used small interfering RNA (siRNA) to knock down Bmal1 expression in WT primary astrocyte cultures. This method resulted in a 95% decrease in BMAL1 protein ( Figures 2C and 2D ) and a 66% decrease in expression of the BMAL1 target Nr1d1 (which encodes REVERBa) ( Figure S2A ). Bmal1 knockdown (KD) in astrocytes induced a highly consistent (across 14 independent experiments) 36% increase in Gfap mRNA expression ( Figure S2A ) as well as a 68% increase in GFAP protein (Figures 2C and 2D) . We also saw significant increases in the astrocyte activation marker S100a6 (1.7-fold), the cytokine Il6 (2.4-fold), and Il33 (1.6-fold) ( Figure S2A ), an astrocytic cytokine implicated in astrocyte-microglia signaling (Wicher et al., 2017) . Bmal1 KD in primary astrocytes from Per2-luciferase reporter mice caused a loss of circadian Per2 rhythms ( Figure 2E ). Thus, disruption of circadian function via KD of Bmal1 in WT astrocytes induces a cell-autonomous reactive phenotype in vitro.
We next sought to confirm these findings by specifically deleting Bmal1 in astrocytes in vivo. We found that intracerebroventricular injection of an AAV8 viral vector expressing EGFP under a Gfap promoter (AAV8-GFAP-EGFP) on postnatal day 2 led to widespread EGFP expression in resting astrocytes throughout the cerebral cortex, with almost no neuronal labeling ( Figures 2F, 2G , and S2B). Thus, we injected P2 Bmal1 f/f mice either with AAV8-GFAP-GFP or with an identical virus expressing a Cre-GFP fusion protein (AAV8-GFAP-Cre GFP ). At 5 months, we observed Bmal1 deletion and increased GFAP expression specifically in astrocytes expressing AAV8-GFAP-Cre GFP ( Figure 2F ). The GFAP-Cre GFP vector exhibits very weak nuclei-restricted fluorescence, making it more difficult to see than that of the AAV8-GFAP-EGFP vector.
Mice treated with the EGFP control vector had widespread astrocyte labeling throughout the cingulate and retrosplenial cortices, intact BMAL1 expression, and very little astrocyte activation as defined by GFAP immunoreactivity (Figures 2F and 2G ). Mice injected with the Cre GFP vector showed astrocytic nuclear GFP expression and 3.4-and 3.1-fold increases in GFAP immunoreactivity in the cingulate and retrosplenial cortices, respectively ( Figure 2G ). Finally, we generated tamoxifen-inducible astrocytespecific Bmal1 KO mice using an Aldh1l1-Cre ERT2 driver line (Aldh1l1-Cre
ERT2
;Bmal1 f/f mice) (Srinivasan et al., 2016) . We treated Cre+ and CreÀ mice with tamoxifen at 1 month and examined astrocyte activation at 3 months. We observed specific deletion of Bmal1 in astrocyte nuclei of the hippocampus and cortex ( Figures S2D and S2E ). Aldh1l1-Cre+ mice had significant increases in astrogliosis, as assessed by GFAP immunostaining in the hippocampus ( Figure 2H ), and a nearly significant (p = 0.055) increase in the retrosplenial cortex ( Figure S2C Figures 2H and S2C ). Ald1l1-Cre+ mice also had spontaneous and significant increases in a number of additional astrocyte activation transcripts including S100a6 (2.5-fold), C4b (2.6-fold), Cxcl5 (7.5-fold), and Mmp14 (3.1-fold) ( Figure S2F ). In total, these experiments demonstrate that Bmal1 deletion in astrocytes can induce activation in a cell-autonomous manner. While activated astrocytes generally exhibit morphologic changes and increased GFAP expression, the transcriptional profile of activated astrocytes is heterogeneous and can define their function (Liddelow et al., 2017; Zamanian et al., 2012) . In order to examine the transcriptional profile in the brain following Bmal1 deletion, we performed microarray analysis of cortical tissue from 11-month-old NBmal1 KO mice, CreÀ controls, and Per1
Brdm

/Per2
Brdm (Per1/2 mut ) mice placed in constant dark conditions for 36 hr and then harvested at clock time (CT) 6:00 and 18:00. Per1/2 mut mice were included because they have a dysfunctional circadian clock but no astrogliosis phenotype as well as tonically increased levels of BMAL1 transcriptional targets ( Figures 3A and S3A ). To understand astrocyte transcriptional changes in NBmal1 KO brain, we examined the overlap between the 200 most upregulated transcripts in NBmal1 KO with the 200 most astrocyte-enriched transcripts according to the Barres lab RNA-sequencing (RNA-seq) database (Zhang et al., 2014) (Figure 3A) . Thirty genes overlapped, including Gfap, Aqp4 (encoding the astrocytic water channel aquaporin-4), and Megf10, a gene involved in astrocyte-mediated synaptic elimination (Chung et al., 2013) . C4b, a complement cascade component also implicated in synapse elimination and a marker of astrocyte activation and aging (Boisvert et al., 2018; Clarke et al., 2018) , was strongly upregulated (4-fold) in NBmal1 KO brain. Several other diseaseassociated astrocytic genes were increased in NBmal1 KO brain, including inflammatory mediators such as Cxcl5 and Ccr7 and the matrix metalloproteinases Mmp14 and Mmp2. Nearly all of these transcripts were either unchanged or decreased in Per1/2 mut mice, demonstrating the key role of decreased BMAL1 function in this phenotype. We next performed microfluidic qPCR profiling of global Bmal1 KO hippocampal samples for markers of astrocyte activation and polarization (Liddelow et al., 2017) , which demonstrated that Bmal1 deletion increased most pan-reactive markers but did not clearly polarize astrocytes toward a neurotoxic or neurotrophic profile ( Figure 3B Figure 1A ), is needed to induce astrocyte activation. In order to determine if Gfap and other selected activation markers are clock-controlled genes, we harvested cortex All data represent mean + SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by 2-tailed t tests (C) and (G) or 1-way ANOVA (H) with Holm-Sidak correction for multiple comparisons when applicable.
from 4-month-old NBmal1 KO and Cre-controls at 4-hr intervals across one circadian cycle in constant darkness. Gfap mRNA levels showed no circadian oscillation in control or Cre+ mice and were elevated across the circadian cycle in Cre+ mice. These findings were duplicated in other markers of astrocyte activation, including Aqp4 and Mmp14 (Figure S3B) . Thus, the astrogliosis phenotype in Bmal1 KOs is not likely due to direct regulation of Gfap or other activation markers by the clock.
To address potential mechanisms linking BMAL1 to astrocyte activation, we performed pathway analysis on our NBmal1 KO transcriptomic data using two bioinformatics tools: Ingenuity Pathway Analysis (IPA) and Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Resources 6.8 (Huang et al., 2009) . We analyzed an inclusive list consisting of all transcripts that differed between control and NBmal1 KO at 6 p.m. with uncorrected p values < 0.01 (Table S1 ). IPA canonical pathway analysis identified glutathione-mediated detoxification ). Inducible Bmal1 KO mice and CreÀ control littermates were treated with NAC before, during, and after 5-day tamoxifen treatment to delete Bmal1. Mice were harvested 9 days after the start of tamoxifen. n = 6-10 mice per group. All data represent mean + SEM. *p < 0.05, ***p < 0.001 by t test with Holm-Sidak correction for multiple comparisons.
as the top hit ( Figure 3C ; p = 0.000013). Functional annotation clustering with DAVID showed that the most enriched gene cluster focused on glutathione-S-transferase (GST) activity, and 4 of the top 5 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways identified were related to glutathione metabolism (Figure S3C) . GST enzymes catalyze the phase II detoxification of reactive intermediates in cells via adduction to glutathione and can alter cellular signaling via glutathionylation of proteins (Grek et al., 2013) . We found that expression of several GST isoforms was suppressed in NBmal1 KO cortex and increased in Per1/2 mut cortex ( Figure 3D ), suggesting reciprocal regulation by the positive and negative limbs of the circadian clock. In support of our microarray analysis, we observed significant decreases in 2 of the 3 GST isoforms probed in cortex from 3-month-old CAG-Cre+;Bmal1 f/f mice 9 days after tamoxifen treatment ( Figure S3D ) and in 1 of the 3 GST isoforms probed in hippocampus from 3-month-old Aldh1l1-Cre+ mice 2 months after tamoxifen treatment ( Figure S3E ). We next asked if altered glutathione homeostasis within astrocytes linked Bmal1 deficiency with astrocyte activation. Our data clearly show that Bmal1 deletion induced changes in both Gfap mRNA and GFAP protein, which are very closely correlated across all models (see Figure S4A ), so Gfap mRNA was used as a marker for astrogliosis in subsequent experiments. Treatment with N-acetyl cysteine (NAC), a glutathione precursor, completely prevented increased Gfap expression in astrocytes following Bmal1 KD ( Figure 3E ). Conversely, incubation of WT astrocytes with buthionine sulfoxime (BSO), which blocks glutathione production, lowered cellular glutathione levels ( Figure S3F ) and caused an increase in Gfap mRNA similar to that observed with Bmal1 KD ( Figure 3E ). Treatment of Bmal1-deficient astrocytes with BSO did not induce a further increase in Gfap, suggesting that BSO and Bmal1 KD are causing increases in Gfap through overlapping pathways. Interestingly, neither Bmal1 KO nor KD of Bmal1 in cultured primary astrocytes altered glutathione levels ( Figure S3F ). Additionally, the oxidation state of glutathione (ratio of reduced GSH to oxidized GSSG) was not altered in cortex from NBmal1 KO or Per1/2 mut mice ( Figure S3G ).
As glutathione levels and oxidation state remained unchanged with loss of Bmal1, we next examined glutathione signaling via glutathionylation, which has been shown to oscillate in a circadian manner in the SCN (Wang et al., 2012) . Western blot analysis of WT astrocytes treated with biotin-linked glutathione ethyl ester (bioGEE) revealed widespread changes in the pattern of S-glutathionylated proteins in Bmal1 KD cells, which were similar to changes seen in BSO-treated controls ( Figure 3F ). In general, numerous bands showed increased biotin labeling, indicating decreased glutathionylation, as would be expected with decreased GST expression. These data suggest that the observed astrogliosis may be due at least in part to altered protein glutathionylation resulting from impaired expression of specific GSTs. We next examined whether bolstering glutathione signaling can prevent astrogliosis following Bmal1 deletion in vivo. We previously showed that tamoxifen-inducible global Bmal1 deletion in mice (CAG-Cre+;Bmal1 f/f mice) causes astrocyte activation (Yang et al., 2016) . We treated CAG-Cre+;Bmal1 f/f mice with NAC in their drinking water (40 mM beginning 5 days before tamoxifen) and via intraperitoneal injection (150 mg/kg daily beginning 2 days before tamoxifen) and induced Bmal1 deletion via tamoxifen administration for 5 days. Both administrations of NAC were continued for the duration of the experiment. Cortex was harvested 9 days after the start of tamoxifen treatment and analyzed by qPCR. Tamoxifen treatment induced an 87% loss in Bmal1 and a 79% loss in expression of the Bmal1 target Nr1d1 (Figure S3H ), as well as a 64% increase if Gfap expression ( Figure 3G ). Administration of NAC was able to provide a significant but partial rescue of the Gfap increase seen in CAGCre+;Bmal1 f/f animals ( Figure 3G ). These results suggest that Bmal1 regulates Gfap expression at least in part through modulation of glutathione signaling in vivo.
Finally, we examined potential pathogenic consequences of Bmal1 deletion in astrocytes. We generated primary astrocyteenriched cultures from CAG-Cre+;Bmal1 f/f mice and CreÀ littermates and treated them with tamoxifen in vitro to delete Bmal1. These cultures are primarily astrocytes, but this methods yields cultures which contain $2% microglia and/or oligodendrocyte precursor cells (Schildge et al., 2013) . Primary WT cortical neurons were then co-cultured on these astrocytes for up to 12 days, and a subset was subjected to oxidative stress by hydrogen peroxide exposure (100 mM H 2 O 2 ) for 24 hr ( Figure 4A Figures 4D and 4E ). This finding shows that Bmal1-deficient astrocytes are less able to sustain neuronal viability, particularly in the face of oxidative stress.
DISCUSSION
Despite a large body of evidence describing circadian disruptions in both aging and neurodegenerative disease, little is known about the implications of circadian dysfunction on the brain. Here, we provide evidence that behavioral circadian disruption or disruption of the astrocytic molecular clock via manipulations of the master clock gene Bmal1 induce astrogliosis and astrocyte dysfunction. The critical but complex role of astrocytes in brain pathologies and neuroinflammation underscores the importance of elucidating mechanisms of astrocyte activation, and our data illuminate BMAL1 as a potent regulator of astrocyte activation by both cell-autonomous and non-autonomous mechanisms. The existence of the astrocyte circadian clock has been well documented (Prolo et al., 2005) , and the critical role of the astrocyte clock in maintaining circadian rhythms in the SCN has recently been described (Barca-Mayo et al., 2017; Brancaccio et al., 2017; Tso et al., 2017) . Clock genes have been shown to regulate astrocytic glutamate uptake and ATP release (Beaulé et al., 2009; Marpegan et al., 2011) , but the function of the core clock in astrocytes is otherwise unexplored. We have shown here, using several in vitro and in vivo methods, that loss of Bmal1 function in astrocytes causes cell-autonomous astrocyte activation. However, deletion of Bmal1 specifically in neurons also induces a partial astrocyte activation phenotype, suggesting a coexistent cell-non-autonomous mechanism. Bmal1 deletion in cultured neurons causes toxicity (Musiek et al., 2013) , implicating a possible damage signal from Bmal1-deficient neurons that activates nearby astrocytes. Alternatively, the neuronspecific Bmal1 KO mice used in this study are behaviorally arrhythmic (Izumo et al., 2014) , and this loss of rhythms could induce astrocyte activation, as seen in 10 hr:10 hr L:D-exposed animals ( Figure 1 ). Thus, cell-non-autonomous influences on glial activation in the brain must be examined in the future.
One important question is whether the loss of rhythmic function of the circadian clock plays a key role in this phenotype or if this is a ''non-circadian'' function of BMAL1. Our data suggest that arrhythmicity in the setting of increased BMAL1 expression, as in Per1/2 mut mice, does not induce astrocyte activation, as these mice express increased levels of GSTs. Thus, astrocyte activation appears to be dependent on suppression of BMAL1-mediated transcription. However, BMAL1 DNA binding is highly rhythmic and regulated by the clock ( difficult to separate entirely from circadian rhythms. Bmal1 KD in astrocytes abrogates circadian Per2-luc oscillations, which could contribute to increased Gfap expression in cell culture. Moreover, we show in Figure 1 that circadian disruption by exposure of mice to 10 hr:10 hr L:D conditions, which blunts Bmal1 oscillations in the brain, can induce Gfap expression. Thus, dampening the rhythmicity of BMAL1 expression through circadian clock disruption likely plays a role in mediating astrogliosis, perhaps by restricting BMAL1 levels at certain key times of day. BMAL1 levels can be suppressed by several factors such as aging (Wyse and Coogan, 2010) , inflammation (Curtis et al., 2015) , or amyloid-beta (Song et al., 2015) , all of which could potentially influence astrocyte activation and function in a BMAL1-dependent manner.
The activation profile induced in Bmal1-deficient astrocytes encompasses upregulation of a variety of genes across the predefined neurotoxic, neurotrophic, and pan-reactive categories (Liddelow et al., 2017) . However, it is important to remember that these astrocyte phenotypes are thought to be induced by cytokine release from microglia, whereas activation due to loss of Bmal1 can be cell autonomous. Our findings contrast with those of Nakazato et al., who found that S100b-Cre+;Bmal1 f/f mice did not develop astrocyte activation and attributed the astrocyte activation phenotype of Nestin-Cre+;Bmal1 f/f mice to pericyte dysfunction (Nakazato et al., 2017) . While our data do not exclude a contribution of blood-brain barrier dysfunction to the Nestin-Bmal1 phenotype, we provide multiple lines of evidence demonstrating cell-autonomous astrocyte activation. While Bmal1-deficient astrocytes do not assume a clear neurotoxic (''A1'') phenotype, they are less able to support neuronal survival in a co-culture system and express numerous transcripts associated with inflammation and neurodegeneration.
These include C4b, a complement component and marker of astrocyte activation and aging (Boisvert et al., 2018; Clarke et al., 2018) , Megf10, which mediates astrocytic synapse elimination (Chung et al., 2013) , and Pla2g3, a phospholipase implicated in ROS-induced neuronal damage (Martínez-García et al., 2010) . Activation marker Lcn2 (lipocalin 2), an anti-inflammatory mediator in the brain (Kang et al., 2018) , was not increased, again suggesting a pro-inflammatory state. Our data support a mechanism in which loss of BMAL1 induces astrogliosis through disruption of GST-mediated protein glutathionylation. In addition to its role in quenching oxidative stress, glutathione can form adducts on cysteine residues in a process termed glutathionylation, which is catalyzed by GSTs and can serve a signaling function (Grek et al., 2013; Mailloux and Treberg, 2016) . Circadian rhythms of protein S-glutathionylation in the SCN may regulate neuronal excitability (Wang et al., 2012) . Because Bmal1-deficient astrocytes have normal total glutathione levels, it is likely that disruption of GST-mediated glutathione signaling or utilization, but not glutathione depletion, mediates BMAL1-controlled astrogliosis. Accordingly, we observed an altered pattern of protein S-glutathionylation in Bmal1-deficient astrocytes, which resembled that seen in BSO-treated cells. Thus, supplementing Bmal1-deficient astrocyte cultures or mice with NAC presumably prevents astrogliosis by promoting nonenzymatic glutathionylation of protein targets, thereby circumventing the loss of GSTs. Further studies are needed to identify specific glutathionylation targets that mediate astrocyte activation and understand regulation of astrocyte glutathione signaling in health and disease.
In summary, our data identify the circadian clock protein BMAL1 as a cell-autonomous regulator of astrocyte activation and neurotrophic function and posit altered GST-mediated protein glutathionylation as a mediator of this effect. Our findings suggest that BMAL1 serves as a link between the core circadian clock and astrogliosis and provide insights into how the circadian clock might influence neurodegeneration.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Nestin-Cre+, CAG-Cre ERT2 +, Global Bmal1 KO, Aldh1L1-Cre ERT2 +, and Bmal1 f/f mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and were bred at Washington University. Camk2a-iCre+;Bmal1 f/f mice were bred at University of Texas Southwestern. All cohorts of mice were mixed sex with ages specified in figure legends. All mice were backcrossed at least 10 generations and were maintained on a C57Bly6 background and housed under 12-hour light/12-hour dark conditions. In all cases, a Cre+; Bmal1 f/f male mouse was bred with Bmal1 f/f females to generate an equal mix of Cre-and Cre+ mice, all on the Bmal1 f/f background.
All littermates were thus used for experiments. Aldh1L1-Cre ERT2+ and CAG-Cre ERT2+ mice (Cre-and Cre+ littermates from several litters) were given tamoxifen (Sigma, dissolved in corn oil, 2mg/mouse/day for 5 days) by oral gavage at 1mo or 2mo, respectively, to induce Bmal1 deletion in the applicable tissue. Behavioral circadian desynchronization experiments were performed at Washington State University, using adult male C57BL/6N mice (age 5-6 weeks on arrival, Harlan Envigo). All mice were group housed for gene expression experiments (N = 4-5 per cage), or singly housed for actigraphy, with food and water available ad libitum.
All mouse experiments were conducted in accordance with protocols approved by the Washington University Department of Comparative Medicine, or by the IACUCs at UTSW or WSU. Technologies) . Cortices were dissected, stripped of meninges in ice-cold DMEM, and incubated in 0.05% Trypsin-EDTA (Life Technologies) at 37 C for 15 (neurons) or 20 (astrocytes) minutes. 37 C DMEM plus 10% FBS (GIBCO) was then added to neutralize trypsin, cortices were spun down for 5 minutes at $300 g and gently triturated in 37 C DMEM plus 10% FBS (GIBCO). For astrocytes cultures, cells were then plated on 10cm or T75 tissue culture plates (coated for 2 hours at 37 C with 50 mg/mL poly-D-lysine (PDL-MP Biosciences, Santa Ana, CA), then rinsed twice with ddH 2 O) at a concentration of 2 cortices (1 brain) per plate. Astrocytes were then grown to confluence ($10 days), then shaken at 37 C in a heated shaker at 225 rpm for 2 hours, followed by media change to remove adherent microglia. Cells were later lifted using Trypl-E dissociation reagent (Life Technologies) for 5 minutes at 37 C, washed with DMEM plus 10% FBS, and replated on 12-well (mRNA experiments),
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REAGENT or RESOURCE SOURCE IDENTIFIER
Il6 Taqman Gene expression assay Applied Biosystems Mm00446190_m1
Il33 Taqman Gene expression assay Applied Biosystems Mm00505403_m1
C4b Taqman Gene expression assay Applied Biosystems Mm00437893_g1
Cxcl5 Taqman Gene expression assay Applied Biosystems Mm00436451_g1
Mmp14 Taqman Gene expression assay Applied Biosystems Mm00485054_m1
Timp1 Taqman Gene expression assay Applied Biosystems Mm01341361_m1
Dbp Taqman Gene expression assay Applied Biosystems Mm00497539_m1
Gsta2 Taqman Gene expression assay Applied Biosystems Mm03019257_g1
Gsta4 Taqman Gene expression assay Applied Biosystems Mm00494803_m1
Gstt3 Taqman 
METHOD DETAILS
Behavioral Desynchronization Activity was monitored by implanted Mini-mitter telemetry device (Star BioSciences). For circadian desynchronization, mice were transferred into a 20h light/dark cycle, with 10h of light ($200 Lux) and 10h of dark for 6 weeks then harvested as described below at CT0, 6, 12, and 18; N = 4-5/group/time.
Intracerebroventricular injections
Bmal1 f/f mice were injected on postnatal day 2 (P2) with either AAV8-GFAP-GFP or AAV8-GFAP-Cre GFP viral vectors (2 mL, bihemispheric, from UNC viral vector core), using a 30 g Hamilton syringe (10ul, 45 degree bevel) with a cuff to ensure proper depth (1.5mm). The injection site was 1mm lateral and 1mm posterior to bregma. Mice were housed as described above, harvested at 5 months of age and analyzed as described in the immunohistochemisty section.
Immunohistochemistry
Mice were anesthetized by i.p. pentobarbital (150mg/kg), followed by perfusion for 3 minutes with ice-cold Dulbecco's modified PBS (DPBS) containing 3 g/l heparin. One hemisphere was post-fixed in 4% paraformaldehyde for 24 hours (4 C), then cryoprotected with 30% sucrose in PBS (4 C) for 48 hours. 50-micron serial coronal sections were then cut on a freezing sliding microtome and stored in cryoprotectant solution (30% ethylene glycol, 15% sucrose, 15% phosphate buffer in ddH20). Sections were washed in Tris buffered saline (TBS), blocked for 30 minutes in TBSX (TBS with 0.25% Triton X-100 (Sigma-Aldrich, St. Louis, MO)) containing 3% goat serum, then incubated overnight in TBSX containing 1% goat serum plus primary antibody at 4 C. Sections were then washed in TBS, incubated for 1 hour at room temperature in TBSX with 1:1000 fluorescent secondary antibody, and mounted on slides using Fluoromount G. Epiflourescent images were obtained on a Nikon Eclipse 80i fluorescent microscope. A Nikon A1Rsi scanning confocal microscope was used at 20x for Ki67/GFAP co-localization, at 40x for Aldh1L1-Cre BMAL1/GFAP quantification, and at 60x for viral injection and representative Aldh1L1-Cre co-localization pictures.
Culture experiments
For neuronal cultures, triturated cells were transferred to a second tube to remove debris, then diluted in Neurobasal+B27+glutamine (Life Technologies) and counted prior to plating on astrocyte beds. For co-culture experiments, astrocytes were grown to confluence after replating in 48-well plates and neurons were added immediately following primary dissection at a concentration of 37,500 cells/ well in Neurobasal media plus B-27 supplement and glutamine. After 48 hours, 50% of the media was changed to Neurobasal plus antioxidant-free B-27 (AOF B-27, Life Technologies) and glutamine. Subsequently, 50% media changes were performed using Neurobasal plus AOF B-27 and glutamine every 3 days until neuronal DIV 7 or 11. In cultures grown to DIV 11, half of the wells received 100 mM H 2 O 2 for 24 hours. All wells were then fixed with 4% paraformaldehyde for 15 minutes, washed 3x with TBS and stained for MAP2, CleavedCaspase-3 or NEUN and quantified using protocol in immunoreactivity quantification section.
Immunoreactivity quantification GFAP and MAP2 staining were quantified from 10x images using ImageJ software (NIH). GFAP 8-bit images were thresholded by hand to encompass all GFAP immunoreactivity, and a threshold value was set and maintained for all sections. GFAP percent area coverage was then calculated for each image. In general, 1 image from each section and 2-3 sections/mouse were averaged, and the average from each mouse used as a data point. For Ki67/GFAP co-localization, puncta were hand-counted from maximal intensity projections of z stacks in each region of interest. GFAP, BMAL1, and DAPI co-localizations were hand counted by 2 independent, blinded experimenters in 6 images/mouse (3 hippocampus, 3 cortex) with the average for each mouse reported. CleavedCaspase-3 puncta co-localizing with MAP2 were hand counted by 2 independent, blinded experimenters in 3-5 images/well over 11 wells from 3 independent experiments with averages/well reported. qPCR Flash-frozen brain tissue was homogenized with a mechanical homogenizer for 20 s in RNA kit lysis buffer (PureLink TM RNA Mini Kit, Life Technologies, Carlsbad CA) plus 1% b-mercaptoethanol. RNA was then purified using the kit protocol. Cell lysates were homogenized in TRIzol (Life Technologies). The aqueous layer was then utilized, after chloroform extraction (added 1:5, sample then spun at 13000xg for 15 minutes), in RNA isolation using the kit protocol. RNA concentration was then measured by Nanodrop spectrophotometer and cDNA was made using a high capacity RNA-cDNA reverse transcription kit (Applied Biosystems/Life Technologies) with 1 mg RNA used per 20 mL reaction. Real-time quantitative PCR was performed with ABI TaqMan primers and ABI PCR Master Mix buffer on either the ABI StepOnePLus or QuantStudio 12k Real-Time PCR thermocyclers. During analysis, mRNA measurements were normalized to b-actin (Actb) mRNA levels. All Taqman qPCR primers were obtained from Thermo/Fisher.
Microfluidic qPCR was performed on flash frozen hippocampal tissue from 6mo Global Bmal1 KO and WT littermates mice at Stanford University using a BioMark Real-Time PCR system (Fluidigm, South San Francisco, CA) and analyzed as previously described (Liddelow et al., 2017) .
Western blotting
Tissue samples were homogenized by sonication radioimmunoprecipitation (RIPA) buffer (Cell Signaling Technologies, Danvers MA) containing cOmplete protease inhibitors (Roche Lifesceinces USA, Indianapolis IN). Invitrogen nuPAGE Novex gels, SDS running buffer, and an iBlot transfer device were utilized per the manufacturer's instructions (Life Technologies). Bands were visualized using Lumigen TMA-6 chemiluminescence reagents (Lumigen, Southfield MI) on a Syngene GBOX imaging system. Band density was calculated using ImageJ software and normalized to ERK as a loading control.
Microarray 11mo NBmal1 KO, Cre-littermate, and Per1/2 mut mice were placed in constant darkness for 36 hours, then anesthetized with i.p.
pentobarbital in the dark, followed by perfusion. Mice were harvested at CT 6 and 18 (6am and 6pm), 2-4 mice/genotype/time point. RNA was isolated from flash frozen cortex samples as above and submitted to the Genome Technology Access Center at Washington University for quality control, MessageAmp RNA library preparation, and Agilent 4x44k mouse v2 microarray. Raw data was normalized and analyzed using Partek Genomics Suite v6.6. For DAVID analysis, version 6.8 was used. The gene list from Table  S1 was uploaded using Official Gene Symbol as the identifier, species = Mus musculus, and 692/842 genes were recognized. ). An siRNA:RNAiMAX ratio of 1:1.25) was used, and 40 pmol of siRNA (2uL of 20uM stock) was added to each well, using 12-well plates. Media was changed 24-48 hours later.
BSO and NAC experiments
For NAC experiments, astrocytes were incubated in growth media supplement with 1mM N-acetylcysteine (Sigma) starting 24 hours after transfection with siRNA, and for the remainder of the experiment. 72 hours before harvest, media was changed to DMEM plus 2% FBS and, where indicated, containing 250 mM buthionine sulfoxime (BSO, Sigma) and cells were harvested as described above at day 8 after siRNA treatment. CAG-Cre+;Bmal1 f/f mice and Cre-littermates (age 2-3 mo) used for in vivo NAC experiments were given either control drinking water or water containing 40mM NAC starting day 0 until sacrifice. Beginning on day 3 and continuing until sacrifice, mice were also given daily intraperitoneal injections of NAC (150mg/kg) or sterile DPBS for controls. Tamoxifen (Sigma, dissolved in corn oil, 2mg/mouse/day for 5 days) was administered by oral gavage to all mice beginning day 5 after water treatment. Water was refreshed once at day 7. Mice were perfused at day 14 (4 days after completion of tamoxifen) and tissue was prepared as described above.
Per2:luciferase Bioluminescence Recording
Primary astrocyte cultures were prepared from P1-2 PER2::LUC transgenic mice, and transfected with siRNA as above. 48 hours later, cells were synchronized by media change, and PER2::LUC activity was continuously monitored from a photomultiplier tube (HC135-11MOD, Hamamatsu) from transfected cortical astrocytes plated on a sealed 35mm Primaria dish (BD Biosystems, San Diego, CA) with 1 mL of serum-free DMEM supplemented with 2% B27 (Invitrogen), pen/strep, 10 mM HEPES, 0.35 g/L NaHCO3, 4.5 g/L D-glucose, 2% L-glutamine, and 0.1 mM beetle luciferin (Promega,Madison,WI). Acquired in vitro bioluminescence traces were detrended by division over a 24h running average and fitted with a damped sine function (Chronostar 2.0, PMID: 19299560) . Only traces with a coefficient of correlation > 0.80 and period between 18-30h were considered circadian and rhythmic.
BioGEE glutathionylation assay
Primary astrocyte cultures were prepared and transfected with siBmal1 and siSCR siRNA as described above. At day 5 post-transfection media was changed to DMEM, +2% FBS, +penicillin/streptomycin. Also at day 5, 250uM BSO (Sigma) was added to a subset of wells to block glutathione synthesis. At day 7 post-transfection all media was refreshed (DMEM, +2% FBS, +penicillin/ streptomycin, +250uM BSO where appropriate) and 100uM BioGEE Glutathiolation Detection Reagent (Invitrogen, G36000) was added to each well except for one (non-treated control). After 3 hours, cells were lysed in RIPA buffer and processed as in western blotting section. As the entire size range of membrane was needed to blot for glutathione ethyl ester linked biotin, a parallel gel was run using the same sample mix in order to blot for loading control (p42/44 ERK). After transfer, the loading control membrane was blotted and imaged as above in the western blotting section. The membrane for detection of glutathionylation was washed and blocked as above except that TBS-T (tris buffered saline +0.125 tween) was replaced with PBS-T (phosphate buffered saline +0.125% tween) per method recommendation. After blocking, membrane was placed in 5% milk in PBS-T +streptavidin poly-HRP40 conjugate (Fitzgerald, Boston, MA, 65R-S104PHRP, 1:2000) for 1 hour, washed 5 times in PBS-T and imaged as in western blotting section.
Glutathione Measurements GSH and GSSG levels were quantified in mouse cortex samples using the Glutathione Assay Kit (Cayman Chemical, Ann Arbor, MI). In cell culture experiments, glutathione measurements were obtained at day 7 using the Intracellular Glutathione Detection Assay Kit (Abcam, Cambridge, MA) by kinetic read (beginning immediately upon adding reagent and then every 5 minutes for 60 minutes) on a Tecan Infinite M1000 Pro fluorescent plate reader (Tecan, Switzerland).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prizm v7.02. In general, data are represented by mean ± SEM. In mouse experiments, ''n'' represents the number of mice and in cell culture experiments ''n'' represents the number of biological replicates. Specific statistical tests used, p value level definitions, and additional details are listed in figure legends. When multiple t test were performed, Holm-Sidak correction test for multiple comparisons was applied unless otherwise noted.
DATA AND SOFTWARE AVAILABILITY
The accession number for the microarray data reported in this paper is ArrayExpress: E-MTAB-7151. Array available at https://www. A. Representative actigraph of a WT mouse housed in 12h:12h light:dark, then switched to 10h:10h light:dark at black arrow, leading to behavioral arrhythmicity.
B. Cortical qPCR showing mRNA levels from 10h:10h light:dark WT mice from Fig. 1A , S1A reveals increased Gfap expression at most timepoints throughout the circadian day.
C. Hippocampal (top, scale bars = 150μm) and cortical (bottom, scale bars = 50μm) staining of NEUN (red) and BMAL1 (green) from 4mo Camk2a-iCre+;Bmal f/f mice and Cre-controls shows complete loss of neuronal BMAL1 in Cre+ animals.
D. Representative images (top) and quantification (bottom) illustrating minimal localization of the cell division marker Ki67 staining with GFAP+ astrocytes in cerebral cortex from 4 mo Nestin-Cre+;Bmal1 f/f (NBmal1 KO) mice (left graph), despite large increases in GFAP+ cells as compared to Cre-controls (right graph). Scale bar= 50μm.
E. NBmal1 KO mice have increased GFAP+ activated astrocytes in the cerebral cortex without major changes in number of total (S100B+) astrocytes. Scale bar = 50μm.
All data represent mean+SEM. *p<0.05 by 2-tailed T-test. A. qPCR showing mRNA levels of several astrocyte activation and inflammatory genes 7 days after treatment of WT astrocytes with non-targeting siRNA (siSCR) or siRNA targeting Bmal1 (siBmal1). N=12-15 experiments.
Camk2a-iCre+
B. Representative cortical images from mice in Fig. 2F-H . Top row. AAV8-GFAP-GFP-infected cells (solid arrows) show whole-cell GFP expression, persistent colocalized nuclear BMAL1, and fail to colocalize with neuronal nuclei (hollow arrows). Bottom row. AAV8-GFAP-Cre infected cells show only nuclear GFP expression (solid arrows, Cre eGFP fusion protein), loss of nuclear BMAL1 and fail to colocalize with neuronal nuclei (hollow arrows). Scale bar= 30µm.
C. Representative images, quantification of %GFAP area in retrosplenial cortex of mice in Fig. 2H . Scale bar = 100µm. All data represent mean+SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by 2-tailed T-tests (A), (E), and (F) or 1-way ANOVA (D) with Hom-Sidak correction for multiple comparisons when applicable. C. Quantification of MAP2 percent area (top) and cleaved-Caspase-3+ (bottom) neurons from (C) shows nonsignificant trends toward decreased MAP2 and increased cleaved-Caspase-3+ neurons when neurons are plated on BMAL1-deficient astrocytes (Cre+).
All data represent mean+SEM. Normalized GFAP or Gfap level 
